Home Who We Are In the News Page 3

In the news.

Donor chooses ACGT for brain cancer research to honor late husband

By giving to ACGT to fund brain cancer research, Lori Lowe contributes to the legacy that her husband Ming Lowe has left behind – a legacy of love, adventure and a desire to make the world a better place.

Donor chooses ACGT for brain cancer research to honor late husband

FDA approves first CAR T-cell therapy for CLL/SLL.

The FDA approved Breyanzi last week as the first CAR T-cell therapy to treat refractory for resistant chronic lymphocytic leukemia and small lymphocytic lymphoma.

FDA approves first CAR T-cell therapy for CLL/SLL.

The FDA approved Breyanzi last week as the first CAR T-cell therapy to treat refractory for resistant chronic lymphocytic leukemia and small lymphocytic lymphoma.

Common questions and answers about TIL therapy for cancer.

The FDA approved the first TIL therapy for cancer on Feb. 16 with the approval of Amtagvi to treat advanced melanoma. Here are common questions and answers about this cancer cell therapy.

Common questions and answers about TIL therapy for cancer.

The FDA approved the first TIL therapy for cancer on Feb. 16 with the approval of Amtagvi to treat advanced melanoma. Here are common questions and answers about this cancer cell therapy.